ESSA Pharma Inc. (EPIX)

NASDAQ: EPIX · Real-Time Price · USD
1.730
-0.010 (-0.57%)
At close: Nov 20, 2024, 4:00 PM
1.670
-0.060 (-3.47%)
Pre-market: Nov 21, 2024, 4:57 AM EST
-0.57%
Market Cap 76.76M
Revenue (ttm) n/a
Net Income (ttm) -27.67M
Shares Out 44.37M
EPS (ttm) -0.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 196,304
Open 1.710
Previous Close 1.740
Day's Range 1.690 - 1.779
52-Week Range 1.400 - 11.670
Beta 1.84
Analysts Hold
Price Target 9.50 (+449.13%)
Earnings Date Dec 10, 2024

About EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouve... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 50
Stock Exchange NASDAQ
Ticker Symbol EPIX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for EPIX stock is "Hold." The 12-month stock price forecast is $9.5, which is an increase of 449.13% from the latest price.

Price Target
$9.5
(449.13% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ESSA Pharma Inc. (EPIX) and Encourages Shareholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:E...

14 days ago - Accesswire

ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:E...

15 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESSWIRE / November 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:E...

16 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating ESSA Pharma Inc. (EPIX) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:E...

17 days ago - Accesswire

ESSA Pharma Inc. (EPIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:E...

19 days ago - Accesswire

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens  A futility analysis ...

20 days ago - PRNewsWire

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten...

2 months ago - PRNewsWire

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.

2 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1...

3 months ago - PRNewsWire

ESSA Pharma to Present at the JonesHealthcare Seaside Summit

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing no...

4 months ago - PRNewsWire

ESSA Pharma to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing no...

6 months ago - PRNewsWire

ESSA Pharma's Speculative Buy Potential: Masofaniten Promise For Prostate Cancer

ESSA Pharma Inc. is developing Masofaniten, a drug that disrupts the androgen receptor to stop prostate cancer growth, with promising results in phase 1 trials. Masofaniten has the potential to overco...

6 months ago - Seeking Alpha

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiand...

6 months ago - PRNewsWire

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing no...

8 months ago - PRNewsWire

ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA , March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing ...

9 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achievi...

10 months ago - PRNewsWire

ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

10 months ago - PRNewsWire

ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Jan. 25, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

10 months ago - PRNewsWire

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scien...

1 year ago - PRNewsWire

ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on deve...

1 year ago - PRNewsWire

ESSA Pharma to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developin...

1 year ago - PRNewsWire

ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance

A phase 2 study is being advanced using EPI-7386 in combination with enzalutamide to treat patients with metastatic castration-resistant prostate cancer; Positive updated PSA data presented at medical...

1 year ago - Seeking Alpha

ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada , Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on devel...

1 year ago - PRNewsWire

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 re...

1 year ago - PRNewsWire

ESSA Pharma Insiders Establish Automatic Securities Disposition Plans

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada , Aug. 31, 2023 /PRNewswire/ - ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developin...

1 year ago - PRNewsWire